Farmacie pro praxi. 2023;19(2):80-85

Treatment of spasticity

Ivana Štětkářová
Neurologická klinika 3. LF UK a FNKV, Praha

Spasticity is one of the serious clinical manifestations of damage to the central motoneuron, which occurs during ischemia, hemorrhage, trauma, inflammation, tumor or as part of neurodegenerative disorders. There are two types of spasticity - cerebral and spinal. In cerebral lesions, there is a loss of the influence of the cerebral cortex on trunk inhibitory structures, while in spinal lesions, spastic dystonia of a severe degree is present and flexor involvement predominates. A careful clinical examination of each patient is important to assess the type and degree of spasticity. A number of scales and questionnaire methods are used for this. Ashworth scale of muscle hypertonia and its modifications are most often used. The goal of spasticity treatment is to improve the function of spastic limbs, enable better independence, reduction of complications, decrease of accompanying pain, and improvement quality of life. The treatment of spasticity consists of rehabilitation, pharmacological or can be solved surgically. Individual treatment procedures are chosen according to the degree and intensity of spasticity, but it also depends on the activities and goals of the specific patient. Treatment of spasticity in most cases begins with a combination of rehabilitation and pharmacological treatment. The most often used drugs are baclofen and tizanidine, or cannabinoids. Focal spasticity can be treated by administration of botulinum toxin into spastic muscle groups. In severe diffuse spasticity, the intrathecal administration of baclofen by continuous pump systems has a very good effect. In some cases, a surgical approach to spasticity treatment (myelotomy, DREZotomy) can also be chosen. The treatment of spasticity is a long-term process and requires multidisciplinary approach.

Keywords: spasticity, pharmacotherapy, baclofen, tizanidine, botulinum toxin, intrathecal baclofen.

Accepted: May 29, 2023; Published: June 7, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štětkářová I. Treatment of spasticity. Pharmacy for Practice. 2023;19(2):80-85.
Download citation

References

  1. Barnes MP, Johnson GR. Upper motor neurone syndrome and spasticity. Cambridge: Cambridge University Press; 2001.
  2. Štětkářová I. Mechanizmy spasticity a její hodnocení. Cesk Slov Neurol N. 2013;76/109(3):267-80.
  3. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004; 10:589-95. Go to original source... Go to PubMed...
  4. Štětkářová I, Ehler E. Hodnocení spasticity. In: Štětkářová I, Ehler E, Jech R (Eds.): Spasticita a její léčba. Maxdorf, 2012:33-58.
  5. Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005;31(5):535-551. Go to original source... Go to PubMed...
  6. Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005 May;31(5):552-71. Go to original source... Go to PubMed...
  7. Jech R. Klinické aspekty spasticity. Neurol. praxi. 2015;16(1):14-19.
  8. Yelnik AP, Simon O, Parratte B, Gracies JM. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med. 2010 Oct;42(9):801-7. Go to original source... Go to PubMed...
  9. Ashworth B. Preliminary trial of carisprodol in multiple sclerosis. Practitioner. 1964;192:540-542
  10. Bohannon RW, Smith MB. Interrater reliability of modified Ashworth scale of muscle spasticity. Phys Ther. 1986;67:206-207. Go to original source... Go to PubMed...
  11. Medical Research Council of the UK. Aids to the Investigation of Peripheral Nerve Injuries. Memorandum No.45. London: Pendragon House.1976:6-7.
  12. Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med. 2010;46:401-10. Go to PubMed...
  13. Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet. 1984;1:1078. Go to original source... Go to PubMed...
  14. Ochs G, Naumann C, Dimitrijevic M, Sindou M: Intrathecal baclofen therapy for spinal origin spasticity. spinal cord injury, spinal cord disease, and multiple sclerosis. Neuromodulation 1999;2(2):108-119. Go to original source... Go to PubMed...
  15. Wissel J, Ri S. Assessment, goal setting, and botulinum neurotoxin a therapy in the management of post­‑stroke spastic movement disorder: updated perspectives on best practice. Expert Rev Neurother. 2022 Jan;22(1):27-42. Go to original source... Go to PubMed...
  16. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997 Oct;35(10):686-9. Go to original source... Go to PubMed...
  17. Legare CA, Raup­‑Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid­‑Based Pharmaceuticals. Pharmacology. 2022;107(3-4):131-149. Go to original source... Go to PubMed...
  18. Pagano C, Navarra G, Coppola L, et al. Cannabinoids: Therapeutic Use in Clinical Practice. Int J Mol Sci. 2022 Mar 19;23(6):3344. Go to original source... Go to PubMed...
  19. Francisco GE, Balbert A, Bavikatte G, et al. A practical guide to optimizing the benefits of post­‑stroke spasticity interventions with botulinum toxin A: An international group consensus. J Rehabil Med. 2021 Jan 1;53(1):jrm00134. Go to original source... Go to PubMed...
  20. Wissel J, Camões­‑Barbosa A, Comes G, et al. Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins (Basel). 2021 Dec 11;13(12):887. Go to original source... Go to PubMed...
  21. Dressler D, Bhidayasiri R, Bohlega S, et al. Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendation of the IAB­‑Interdicsiplinary Working Group for Movement Disorders task force. J Neurol 2017;264(1):112-120. Go to original source... Go to PubMed...
  22. Gracies JM, Esquenazi A, Brashear A, et al. International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017 Nov 28;89(22):2245-2253. Go to original source... Go to PubMed...
  23. Stampacchia G, Gerini A, Mazzoleni S. Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow­‑up. NeuroRehabilitation. 2016 Apr 6;38(4):385-93. Go to original source... Go to PubMed...
  24. Štětkářová I, Brabec K, Mencl L. Intrathecal baclofen in spinal spasticity: frequency and severity of withdrawal syndrome. Pain Physician. 2015;18(4):E633-E641. Go to original source... Go to PubMed...
  25. Javier­‑Ormazábal A, González­‑Platas M, González­‑Sierra E, González­‑Sierra M. Invasive Physiotherapy as a Treatment of Spasticity: A Systematic Review. Degener Neurol Neuromuscul, DiS. 2022 Mar 3;12:23-29. Go to original source... Go to PubMed...
  26. Kesikburun S. Non­‑invasive brain stimulation in rehabilitation. Turk J Phys Med Rehabil. 2022 Mar 1;68(1):1-8. Go to original source... Go to PubMed...
  27. Lazorteh Y, Sol JC, Sallerin B, Verdié JC. The surgical management of spasticity. European J Neurology 2002;9:35-41 Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.